Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Acute coronary syndromes. Lancet. 2022;399(10332):1347–58.

Article  PubMed  PubMed Central  Google Scholar 

Claessen BE, Guedeney P, Gibson CM, Angiolillo DJ, Cao D, Lepor N, et al. Lipid management in patients presenting with Acute Coronary syndromes: a review. J Am Heart Assoc. 2020;9(24):e018897.

Article  PubMed  PubMed Central  Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.

Article  PubMed  Google Scholar 

Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J. 2020;42(3):243–52.

Article  PubMed Central  Google Scholar 

Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–8.

Article  CAS  PubMed  Google Scholar 

Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: a new era of lipid lowering therapy. World J Cardiol. 2017;9(2):76–91.

Article  PubMed  PubMed Central  Google Scholar 

Schwartz GG, Chaitman BR. Initiating PCSK9 inhibition in Hospital for ACS: we can, but does that Mean we should? J Am Coll Cardiol. 2019;74(20):2463–5.

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Reviews. 2021;10(1):89.

Article  Google Scholar 

[https://www.crd.york.ac.uk/prospero/#guidancenotes.

https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials.

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

Article  PubMed  PubMed Central  Google Scholar 

NOS [Available from. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–805.

Article  PubMed  Google Scholar 

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

Article  PubMed  PubMed Central  Google Scholar 

Vavuranakis MA, Jones SR, Ziogos E, Blaha MJ, Williams MS, Foran P, et al. The trajectory of lipoprotein(a) during the Peri- and early postinfarction period and the impact of Proprotein Convertase Subtilisin/Kexin type 9 inhibition. Am J Cardiol. 2022;171:1–6.

Article  CAS  PubMed  Google Scholar 

Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, et al. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with Acute myocardial infarction: the PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771–81.

Article  PubMed  PubMed Central  Google Scholar 

Okada T, Miyoshi T, Doi M, Nosaka K, Tsushima R, Ugawa S et al. Effect of early initiation of Evolocumab on Lipoprotein(a) in patients with Acute myocardial Infarction: Sub-analysis of a Randomized Controlled Trial. J Cardiovasc Dev Dis. 2022;9(5).

Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. Evolocumab for early reduction of LDL Cholesterol Levels in patients with Acute Coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452–62.

Article  CAS  PubMed  Google Scholar 

Hao Y, Yang YL, Wang YC, Li J. Effect of the early application of Evolocumab on blood lipid Profile and Cardiovascular Prognosis in patients with extremely high-risk Acute Coronary Syndrome. Int Heart J. 2022;63(4):669–77.

Article  CAS  PubMed  Google Scholar 

Li T, Zhang Y, Cong H. Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes. BMC Cardiovasc Disord. 2021;21(1):19.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Zhang Y, Zhang B, Chen Z, Wei Y, Chen P, et al. Early initiation of Evolocumab Treatment in Chinese patients with Acute Coronary Syndrome undergoing percutaneous coronary intervention. Clin Ther. 2022;44(6):901–12.

Article  CAS  PubMed  Google Scholar 

Yamashita S, Sakamoto A, Shoji S, Kawaguchi Y, Wakabayashi Y, Matsunaga M et al. Feasibility of short-term aggressive lipid-lowering therapy with the PCSK9 antibody in Acute Coronary Syndrome. J Cardiovasc Dev Dis. 2023;10(5).

Zhao Q, Sun S, Zhou F, Yue J, Luo X, Qu X. The inhibition of Evolocumab on non-infarct-related artery disease in patients with ST-Elevation myocardial infarction. Int J Gen Med. 2023;16:2771–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehta SR, Pare G, Lonn EM, Jolly SS, Natarajan MK, Pinilla-Echeverri N, et al. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. EuroIntervention. 2022;18(11):E888–96.

Article  PubMed  PubMed Central  Google Scholar 

Leucker TM, Blaha MJ, Jones SR, Vavuranakis MA, Williams MS, Lai H, et al. Effect of Evolocumab on atherogenic lipoproteins during the Peri- and early postinfarction period: a Placebo-Controlled, Randomized Trial. Circulation. 2020;142(4):419–21.

Article  PubMed  PubMed Central  Google Scholar 

Ji J, Wei X, Chen W, Wan D, Han W, Liu H. Effects of early PCSK9 inhibitor application on inflammation levels and microcirculatory function after PCI in patients with NSTE-ACS. Am J Transl Res. 2023;15(5):3586–96.

CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Chen X. PCSK9 inhibitors for acute coronary syndrome: the era of early implementation. Front Cardiovasc Med. 2023;10:1138787.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, Bao Q, Song X, Song H, Wei S, Lv J, et al. Effects of loading-dose statins combined with PCSK9 inhibitor pre-treatment before primary percutaneous coronary intervention on the short-term prognosis in patients with ST-segment elevation myocardial infarction. Cardiovasc Innovations Appl. 2022;7(1):998.

Google Scholar 

Iannuzzo G, Gentile M, Bresciani A, Mallardo V, Di Lorenzo A, Merone P et al. Inhibitors of protein convertase Subtilisin/Kexin 9 (PCSK9) and Acute Coronary Syndrome (ACS): the state-of-the-art. J Clin Med. 2021;10(7).

Zanchin C, Koskinas KC, Ueki Y, Losdat S, Häner JD, Bär S, et al. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-rationale and design of the PACMAN-AMI trial. Am Heart J. 2021;238:33–44.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, et al. Effect of Evolocumab on Coronary Plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15(7):1308–21.

Article  PubMed  Google Scholar 

Turgeon RD, Tsuyuki RT, Gyenes GT, Pearson GJ. Cardiovascular Efficacy and Safety of PCSK9 inhibitors: systematic review and Meta-analysis including the ODYSSEY OUTCOMES trial. Can J Cardiol. 2018;34(12):1600–5.

Article  PubMed  Google Scholar 

Wang HF, Mao YC, Xu XY, Zhao SY, Han DD, Ge SY, et al. Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: a meta-analysis focusing on the number needed to treat. Front Cardiovasc Med. 2022;9:1016802.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jarcho JA, Keaney JF. Jr. Proof that lower is Better–LDL cholesterol and IMPROVE-IT. N Engl J Med. 2015;372(25):2448–50.

Article  CAS  PubMed  Google Scholar 

Krychtiuk KA, Ahrens I, Drexel H, Halvorsen S, Hassager C, Huber K, et al. Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart Journal: Acute Cardiovasc Care. 2022;11(12):939–49.

Google Scholar